SCHEMBL3903016

SCHEMBL3903016

Cc1c(Cl)cccc1S(=O)(=O)Nc1ccc2c(c1)c(=O)[nH]n2Cc1ccccc1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NR1I2 O75469 7/20 0.48
GSPT1 P15170 1/20 0.45
DDB1 Q16531 1/20 0.45
CRBN Q96SW2 1/20 0.45
BRD4 O60885 1/20 0.44
ALDH1A1 P00352 2/20 0.42
MEN1 O00255 1/20 0.41
LMNA P02545 1/20 0.41
CYP1A2 P05177 1/20 0.41
CYP3A4 P08684 1/20 0.41
CYP2D6 P10635 1/20 0.41
MAPT P10636 1/20 0.41
CYP2C9 P11712 1/20 0.41
CYP2C19 P33261 1/20 0.41
KMT2A Q03164 1/20 0.41
HIF1A Q16665 1/20 0.40
PKM P14618 1/20 0.40
HSD11B1 P28845 2/20 0.39
AKT1 P31749 1/20 0.39
MYLK Q15746 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3904615 0.93 GSPT1 (0.43) NR1I2GSPT1DDB1CRBNBRD4
SCHEMBL3918595 0.92 GSPT1 (0.42) NR1I2GSPT1DDB1CRBNBRD4
SCHEMBL3904770 0.92 NR1I2 (0.43) NR1I2GSPT1DDB1CRBNBRD4
SCHEMBL3905782 0.90 GSPT1 (0.41) NR1I2GSPT1DDB1CRBNBRD4
SCHEMBL3906958 0.89 LMNA (0.46) NR1I2GSPT1DDB1CRBNBRD4
SCHEMBL3906061 0.87 SLC40A1 (0.43) NR1I2GSPT1DDB1CRBNBRD4
SCHEMBL1818133 0.87 PKM (0.43) NR1I2GSPT1DDB1CRBNBRD4
SCHEMBL1811055 0.86 GSPT1 (0.45) NR1I2GSPT1DDB1CRBNBRD4
SCHEMBL1811576 0.86 HSD17B1 (0.47) NR1I2BRD4MEN1LMNACYP1A2
SCHEMBL3903978 0.86 GSPT1 (0.41) NR1I2GSPT1DDB1CRBNBRD4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-101027286-B Indazolone derivatives as 11b-HSD1 inhibitors HOFFMANN LA ROCHE 2011-05-25 CN claimed
US-7528158-B2 Indazolone derivatives useful as 11b-HSD1 inhibitors HOFFMANN-LA ROCHE INC. (US) 2009-05-05 US claimed
EP-1797042-B1 INDOZOLONE DERIVATIVES AS 11B-HSD1 INHIBITORS HOFFMANN LA ROCHE (CH) 2009-01-07 EP claimed
CN-101027286-A Indazolone derivatives as 11 b-HSD 1 inhibitors HOFFMANN LA ROCHE (CH) 2007-08-29 CN claimed
US-20060069269-A1 Novel indazolone derivatives useful as 11b-HSD1 inhibitors F. HOFFMANN-LA ROCHE AG, A SWISS COMPANY (CH) 2006-03-30 US claimed
CN-101027286-B Indazolone derivatives as 11b-HSD1 inhibitors HOFFMANN LA ROCHE 2011-05-25 CN disclosed
US-7528158-B2 Indazolone derivatives useful as 11b-HSD1 inhibitors HOFFMANN-LA ROCHE INC. (US) 2009-05-05 US disclosed
EP-1797042-B1 INDOZOLONE DERIVATIVES AS 11B-HSD1 INHIBITORS HOFFMANN LA ROCHE (CH) 2009-01-07 EP disclosed
CN-101027286-A Indazolone derivatives as 11 b-HSD 1 inhibitors HOFFMANN LA ROCHE (CH) 2007-08-29 CN disclosed
EP-1797042-A1 INDOZOLONE DERIVATIVES AS 11B-HSD1 INHIBITORS F.HOFFMANN-LA ROCHE AG (CH) 2007-06-20 EP disclosed
WO-2006034804-A1 INDOZOLONE DERIVATIVES AS 11B-HSD1 INHIBITORS F.HOFFMANN-LA ROCHE AG (CH) 2006-04-06 WO disclosed
US-20060069269-A1 Novel indazolone derivatives useful as 11b-HSD1 inhibitors F. HOFFMANN-LA ROCHE AG, A SWISS COMPANY (CH) 2006-03-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060069269-A1 Novel indazolone derivatives useful as 11b-HSD1 inhibitors HSD17B1, HSD11B1, HSD17B7 NR1I2 79/4885GSPT1 1509/4885DDB1 2341/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.